The trial aims to combine personal information, pharmacogenomics data, and machine-learning tools to select the best anti-seizure medication for patients.
The number of technologies to be assessed is vast, and ranges from liquid biopsies and molecular imaging to immunohistochemistry and RNA-seq.
The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.
The company will collaborate the Parker Institute for Cancer Immunotherapy, Institut Gustave Roussy in France, and the University Health Network in Toronto, Canada.
The partners will use Biolidics' circulating tumor cell retrieval system to evaluate the cells' utility as biomarkers of patient response to cancer treatment.
The new partnership will support the analysis of glycans in 30,000 human samples by the end of 2021.
The new initiative, called MEGA+, will extend the process of genomic data sharing to all medical data, including electronic health records and imaging files.
The project plans to sequence 20,000 genomes in 2019, 50,000 by the end of 2020, and a total of 100,000 by the end of 2021 using Oxford Nanopore's PromethIon platform.
Evotec will access Indivumed's IndivuType multi-omics cancer database to discover and develop new precision therapeutics for colorectal cancer.
The companies will use their respective technologies to optimize the cannabinoid profiles and other traits of different cannabis varieties.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.